HYCAMCORD^®(topotecan, as hydrochloride)JACOBSONHK Reg. No. HK-68935 (11 Dec, 2025)

Composition:⁴

• Each vial contains 4 mg topotecan (powder for concentrate for solution for infusion)

• The total content of active substance in the vial provides 1 mg per mL of active substance when reconstituted as recommended

Indication:⁴

HYCAMCORD^® monotherapy is indicated for the treatment of:

• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy

• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate

HYCAMCORD^® in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination

References

4. EMA. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/hycamtin-epar-product-information_en.pdf. [Accessed 23 December 2025].